For its fourth fiscal quarter (ending December 31), Agios Pharmaceuticals Inc (NASDAQ: AGIO) has reported E.P.S. of $-1.69 compared to $-1.72 a year ago. Relative to the consensus estimate of $-1.63, this was a shortfall of $-0.06. For the latest four quarters through December 31, E.P.S. were $11.86 compared to $-6.33 a year ago.
Recent Price Action
Agios Pharmaceuticals Inc (NASDAQ: AGIO) stock closed at $33.30 on 2/13/25 after an increase of 1.5%. However, trading volume in this advance was below average at 74% of normal. The stock has declined -3.1% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Agios Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Agios Pharmaceuticals has a slightly negative Power Rating of 33 and a poor Appreciation Score of 21, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment